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Introduction:  The  7-valent  pneumococcal  conjugate  vaccine  (Prevenar®, Wyeth;  PCV7)  was  introduced  to
the UK  paediatric  immunisation  schedule  in  2006.  This  study  investigates  trends  in  serotypes  and  multi
locus  sequence  types  (STs)  among  cases  of  invasive  pneumococcal  disease  (IPD)  in Scotland  prior  to, and
following,  the  introduction  of PCV7.
Methods:  Scottish  Invasive  Pneumococcal  Disease  Enhanced  Surveillance  has  records  of all  cases  of IPD
in Scotland  since  1999.  Cases  diagnosed  from  blood  or cerebrospinal  ﬂuid  isolates  until 2010  were  ana-
lysed.  Logistic  and  poisson  regression  modelling  was  used  to assess  trends  prior  to and  following  the
introduction  of  PCV7.
Results:  Prior  to PCV7  use,  on average  650  cases  of  IPD were  reported  each  year;  12%  occurred  in those  aged
<5 years  and  35%  affected  those  aged  over  65 years.  Serotypes  in PCV7  represented  47% of cases  (68%  in
<5  year  olds).  The  serotype  and  ST distribution  was  relatively  stable  with  only  serotype  1 and associated
ST  306  showing  an  increasing  trend.  PCV7  introduction  was associated  with a  69% (95% CI:  50%,  80%)
reduction  in  the  incidence  of  IPD among  those  aged  <5  years,  a 57%  (95%  CI: 47%,  66%)  reduction  among
those  aged  5–64  years  but  no  signiﬁcant  change  among  those  aged  65  years  and  over  where  increases  in
non-PCV7  serotypes  were observed.  Serotypes  which  became  more  prevalent  post-PCV7  are  those  which
were  associated  with  STs related  to the  PCV7  serotypes.
Conclusions:  Routine  serotyping  and  sequence  typing  in  Scotland  allowed  the  assessment  of  the rela-
tionship  between  the  capsule  
serotypes  post  PCV7  introduct
to  PCV7  introduction.  This  has
vaccines  and  could  aid  in  pred
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ttp://dx.doi.org/10.1016/j.vaccine.2013.05.079and  the  clones  in  the  post vaccination  era.  Changes  in  the  distribution  of
ion  appear  to be driven  by  associations  between  serotypes  and  STs  prior
 implications  for  the  possible  effects  of  the  introduction  of higher  valency
icting  replacement  serotypes  in  IPD.
© 2013  Elsevier  Ltd.  All rights  reserved.
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. Introduction
Streptococcus pneumoniae (S. pneumoniae) is responsible for a
ubstantial burden of disease, accountable for approximately 1.6
illion deaths annually worldwide [1]. In developed countries, the
ncidence of invasive pneumococcal disease (IPD) is between 8 and
5 cases per 100,000 individuals [2], with studies showing that
ost IPD is attributable to only 20–30 of the 94 pneumococcal
erotypes [3].
Recent studies of serotypes involved in IPD compare pre- and
ost-vaccination periods to examine changes in serotype distri-
ution potentially due to the use of the 7-valent pneumococcal
onjugate vaccine (PCV7). The USA, and other countries subse-
uently, showed great reductions in IPD not limited to vaccine
argeted groups [4]. However, increases in IPD caused by non-PCV7
erotypes, in particular 19A, following PCV7 use have been docu-
ented [4–10].
The pneumococcal capsule is thought to be the main deter-
inant of carriage prevalence and invasiveness and hence the
eterminant of prevalence amongst disease isolates [11,12]. How-
ver, it has been speculated that increases in serotype 19A IPD in
articular are perhaps attributable to a capsular switch event after
eing found associated with a sequence type (ST), ST695, previously
nly linked with vaccine serotype 4 [13,14]. Other studies have doc-
mented increases due to the expansion of multi-drug resistant STs
uch as ST276 and ST320 [15,16]. Thus, it is increasingly important
o examine both STs and serotypes involved in IPD to determine
he potential effectiveness of serotype-speciﬁc pneumococcal vac-
inations.
In September 2006, PCV7 was introduced to the National Health
ervice childhood immunisation schedule in the UK in a three dose
rogramme at age 2, 4, and 13 months, with a catch-up for those
ged up to 2 years. In 2010, 94% of the targeted group had received
hree doses of PCV7 [17].
This study examines trends in serotype and ST distributions
rior to PCV7 use in Scotland, adding to existing reports on the
re-vaccine period in Scotland [18,19]; the effect of PCV7 on IPD
ncidence; trends in serotype and ST distribution post-vaccination;
nd the association between serotype and ST pre- and post-
accination.
. Methods
.1. Data
The Scottish Invasive Pneumococcal Disease Enhanced Surveil-
ance (SPIDER) database contains all cases of IPD, identiﬁed by blood
r cerebrospinal ﬂuid, in Scotland from 1999–2010. The serogroup
esponsible for each case of disease was available for all years;
erotype and ST information was available from 2002.
Clinical isolates (from blood or cerebrospinal ﬂuid) of S.
neumoniae were sent to the Scottish Haemophilus, Legionella,
eningococcus and Pneumococcus Reference Laboratory (SHLM-
RL) after identiﬁcation at diagnostic microbiology laboratories.
hese were grown on Columbia blood agar (Oxoid, UK) at 37 ◦C
nder anaerobic conditions using an anaerobic pack (Oxoid, UK)
nd after a single subculture were stored at −80 ◦C on Protect beads
M-Tech Diagnostics, UK). Isolates were serotyped by a coaggluti-
ation method [20]. Multi-locus sequence typing was performed
s described previously [21–23].
Epidemiological years from winter of one year to the end of
utumn of the next were used ensuring winter seasons were
rouped together since IPD predominantly occurs in winter.
Serotypes and STs were classiﬁed according to their joint occur-
ence prior to PCV7 use (1999–2005) and emergence post-PCV7 (2014) 4356–4363 4357
(2006–2010). STs were classiﬁed as associated with PCV7 serotypes
if they occurred at least once in conjunction with a PCV7 serotype
(labelled PCV7-ST); otherwise they were classiﬁed as not associ-
ated (NonPCV7-ST). STs which only occurred following PCV7 use
were classiﬁed as PostPCV7-ST. The PCV7-ST group was subdivided
into two groups: one with12 STs (9, 36, 113, 124, 138, 156, 162,
176, 205, 206, 246, 311) with a high frequency of co-occurrence
with the PCV7 serotypes (labelled HF PCV7-ST), and a larger group
with low frequency co-occurrence (LF PCV7-ST). Serotypes were
categorised in four groups: PCV7 serotypes (4, 6B, 9V, 14, 18C,
19F, 23F); serotypes not in PCV7 but associated with STs linked
through co-occurrence to PCV7 serotypes (PCV7-ST serotypes);
serotypes not in PCV7 and not associated with STs linked to PCV7
serotypes (NonPCV7-ST serotypes); serotypes which only occurred
post-PCV7 vaccination (PostPCV7 serotypes).
2.2. Statistical analysis
Logistic regression models were used to test whether or
not there was  evidence of a linear trend in the pre-PCV7
(1999/00–2005/06) serogroup, serotype and ST distributions.
Serogroups, serotypes and STs responsible for ≥1% of IPD were con-
sidered. Analyses were conducted for the serogroups for age groups
0–4, 5–64, and ≥65 years separately. Bonferroni adjusted conﬁ-
dence intervals were calculated and the Benjamini and Hochberg
adjustment for multiple testing used in determining the signiﬁ-
cance of the trend [24]. The Benjamini and Hochberg adjustment
was used since no particular hypothesis about which serotypes or
STs would have a trend was speciﬁed. As >20 serotypes and STs
were examined, the standard 5% level would be more likely to
report signiﬁcant trends for one serotype or ST even if no trend
was present.
Poisson regression models were used to assess changes in
IPD incidence. The percentage change in the incidence of PCV7
serotypes and NonPCV7 serotypes from the pre-vaccine to the
post-vaccine period was  assessed by predicting post-vaccination
incidence, allowing for a trend in the pre-vaccination years, and
comparing the observed cases with the predicted as suggested else-
where [25,26]; 95% conﬁdence intervals were used. Cases with
missing age (27, 0.4%) were omitted. For 637 cases (10.1%), no
information on the serogroup was  available. The number of vac-
cine type (VT) or non-vaccine type (NVT) serotypes was  imputed,
separately by year and age group, using observed proportions of VT
serotypes. Imputation of serotype, from serogroup, was  carried out
when serotype information was not available based on observed
proportions of serotypes within serogroups from 2002–2006, sep-
arately by age group. All analysis was  conducted using R versions
2.8–2.12 [27].
3. Results
3.1. Trends in serotype and ST distributions prior to PCV7
From 1999/00–2005/06, on average 650 IPD cases per year were
reported in Scotland, rising from 538 in 1999/00 to 743 in 2002/03.
A subsequent drop occurred, primarily amongst those aged ≥65
years, following the introduction of the 23-valent pneumococcal
polysaccharide vaccine (PPV23) for this age group in 2003, with a
coverage of ∼74%. The number increased to 739 in 2005/06. IPD
was most common amongst the elderly (44% of all cases). 12% of
cases affected those aged <5 years.3.2. Serogroup analysis
Thirty-six different serogroups were identiﬁed in IPD from
1999/00–2005/06. Serogroup 14 was most common, accounting
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Table 1
Results from A) the logistic regression models of serogroups and STs responsible for at least 1% of IPD between 1999/00 and 2005/06 and between 2003/04 and 2005/06,
respectively; B) the logistic regression models of serotypes and STs responsible for at least 1% of IPD between 2006/2007 and 2009/2010, examining evidence of signiﬁcant
trends in the proportion of IPD attributable to each serogroup, serotype and ST.
Part A: Serogroup Count OR 95% CI p-value ST Count OR 95% CI p-value
14 673 0.94 (0.883, 0.997) 0.003 9 213 1.06 (0.804, 1.402) 0.539
9  364 0.97 (0.892, 1.047) 0.230 306 174 1.40 (1.042, 1.869) 0.001
1  331 1.36 (1.238, 1.493) <0.001 162 145 1.03 (0.741, 1.432) 0.797
6  301 0.97 (0.891, 1.057) 0.328 53 126 1.01 (0.700, 1.464) 0.924
19  290 0.98 (0.900, 1.074) 0.595 180 96 1.01 (0.678, 1.508) 0.939
4  273 1.04 (0.946, 1.134) 0.284 191 95 1.24 (0.823, 1.875) 0.134
8  247 0.95 (0.865, 1.044) 0.135 124 85 1.00 (0.658, 1.515) 0.987
23  242 0.94 (0.858, 1.035) 0.084 218 74 1.24 (0.784, 1.956) 0.183
3  220 1.00 (0.902, 1.100) 0.917 199 68 0.72 (0.444, 1.151) 0.045
7  162 1.04 (0.926, 1.167) 0.357 227 63 1.22 (0.750, 1.990) 0.244
18  158 0.98 (0.876, 1.104) 0.685 311 63 0.92 (0.561, 1.498) 0.615
12  131 1.04 (0.914, 1.183) 0.400 246 58 0.97 (0.593, 1.601) 0.883
22  107 0.98 (0.849, 1.125) 0.648 433 48 0.60 (0.314, 1.132) 0.022
20  83 0.95 (0.808, 1.113) 0.360 205 41 1.21 (0.654, 2.228) 0.386
33  71 0.94 (0.789, 1.110) 0.285 176 41 1.18 (0.620, 2.237) 0.468
11  65 0.97 (0.811, 1.160) 0.638 206 40 1.22 (0.652, 2.271) 0.372
15  51 1.01 (0.829, 1.239) 0.864 113 38 1.02 (0.530, 1.965) 0.930
235 35 0.77 (0.390, 1.531) 0.284
36  32 1.19 (0.572, 2.475) 0.499
138 30 1.16 (0.581, 2.295) 0.552
62  30 1.14 (0.531, 2.429) 0.636
65  25 1.63 (0.691, 3.838) 0.106
Part  B: Serotype Count OR 95% CI p-value ST Count OR 95% CI p-value
1 210 0.71 (0.58, 0.86) <0.001 306 139 0.73 (0.58, 0.92) <0.001
8  162 0.85 (0.68, 1.05) 0.026 191 217 1.16 (0.96, 1.39) 0.026
7F  240 1.11 (0.93, 1.34) 0.091 53 123 0.90 (0.71, 1.14) 0.195
3  173 1.00 (0.81, 1.23) 0.997 180 135 1.08 (0.86, 1.35) 0.343
19A  165 1.40 (1.11, 1.75) <0.001 199 128 1.25 (0.98, 1.58) 0.008
22F  130 1.34 (1.04, 1.72) <0.001 433 88 1.51 (1.12, 2.04) <0.001
12F  79 1.10 (0.81, 1.49) 0.372 218 59 1.00 (0.72, 1.40) 0.995
6A  74 0.86 (0.63, 1.17) 0.161 227 46 0.85 (0.58, 1.25) 0.238
9  N 48 0.90 (0.62, 1.32) 0.434 62 45 1.15 (0.78, 1.69) 0.306
11A  54 1.08 (0.75, 1.56) 0.514 235 23 0.80 (0.47, 1.36) 0.232
20  35 0.64 (0.40, 1.02) 0.005 65 23 0.74 (0.43, 1.28) 0.119
33F  43 1.13 (0.75, 1.70) 0.397
15B 31 1.16 (0.72, 1.89) 0.362
23A 28 0.96 (0.58, 1.57) 0.800
N eriod
O denc
w
f
S
p
P
(
a
1
3
P
c
y
4
(
(
t
3
(
(ote: Count is the number of serogroups and STs among IPD cases in the pre-PCV7 p
R–Odds  Ratio associated with a one year change; CI-95% Bonferroni adjusted conﬁ
ith  p-values below the Benjamini and Hochberg adjusted p-value.
or 17% of IPD cases, followed by serogroups 9 (9%) and 1 (8%).
erogroup 1 replaced 14 as the most common in 2005/06. The
roportion of serogroup 1 IPD increased steadily over the pre-
CV7 study period, with evidence of an increasing trend (p < 0.001)
Table 1, Part A). Serogroup 14 was borderline signiﬁcant after
djustment for multiple testing, with a decreasing trend from
999/00–2005/06.
.3. Serotype analysis
From 2003/04–2005/06, 42 serotypes were identiﬁed in IPD.
CV7 serotypes accounted for 47% of cases in this period; 68% of
ases in those <5 years, 40% and 48% in those 5–64 years and ≥65
ears, respectively. The most common serotypes, 14 (15%), 1 (13%),
 (7%), 9V (7%), 8 (6%), 3 (6%), 23F (5%), 6B (4%), 7F (4%) and 19F
4%), were responsible for 71% of IPD.
Evidence of an increasing trend in serotype 1 IPD was found
p = 0.029). No other serotypes were found to have signiﬁcant
rends.
.4. ST analysisThe most common STs in IPD from 2003/04–2005/06 were 9
9%), 306 (9%), 162 (6%), 53 (5%), 180 (4%), 191 (4%), 124 (4%), 218
3%), 199 (3%) and 227 (3%). ST9 was commonly associated with in Part A and serotypes and STs among IPD cases in the post-PCV7 period in Part B;
e interval; p-value is the unadjusted p-value. The entries in bold typeface are those
serotype 14; ∼60% of serotype 14 IPD during this period was ST9.
ST306 was commonly associated with serotype 1. There were 158
STs in IPD in 2003/04, 140 in 2004/05 and 115 in 2005/06, showing
a reduction in diversity over time.
There was evidence of an increasing trend in ST306 IPD from
2003/04–2005/06, compared to the 0.05 signiﬁcance level (Table 1,
Part A). No other STs showed strong evidence of a trend.
3.5. The effect of PCV7 on IPD incidence
From 2006–2010, 2380 cases of IPD were reported. 140 cases
occurred in those aged <5 years, 1239 in those 5–64 years, 1001
in those ≥65 years. Following PCV7 use, PCV7 serotype IPD inci-
dence declined by 97.4% in children under 5 (Table 2). Among those
aged 5–64 years and ≥65 years, a signiﬁcant reduction of VT IPD of
86.3% and 80.4%, respectively, was observed. For those <5 years and
5–64 years, there was no signiﬁcant increase in NVT notiﬁcations
in 2008/09 compared to the predicted incidence (Fig. 1). Among
those aged ≥65 years, a signiﬁcant increase in NVT disease of 46.5%
was observed. The reduction in VT incidence and increase in NVT
incidence resulted in no change in all-type incidence in this group.Almost all NVT serotypes exhibited an increase in disease inci-
dence from the last two  pre-vaccination years to 2008/09 (7F:
153.6%, 3: 26.2%, 8: 42.5%, 19A: 78.7%, 22F: 151.6%, 6A: 31.8%, 12F:
2.3%, 11A: 73.9%, 9N: 33.3%). The exception is serotype 1 which
K.E. Lamb et al. / Vaccine 32 (2014) 4356–4363 4359
Table  2
Incidence rates of the most common non-vaccine type (NVT) IPD serotypes and vaccine type (VT) serotypes in Scotland from 2004/05 to 2009/10.
Incidence
2004/05 (n)
Incidence
2005/06 (n)
Incidence
2009/10 (n)
Change 2009/10 predicted
compared to observed
Change 2009/10 predicted compared
to observed (serotype 1 excluded)
0–4 yrs.
All 38.23 (101) 27.35 (73) 14.18 (41) −68.5% (−80.4, −50.0) −69.8% (−81.7, −50.8)
NVT  12.87 (34) 7.12 (19) 13.49 (39) −39.6% (−71.4, 28.6) −13.4% (−62.4, 102.7)
VT  25.36 (67) 20.24 (54) 0.69 (2) −97.4% (−99.6, −91.3) −97.5% (−99.6, −91.4)
5–64  yrs.
All 8.11 (324) 9.52 (381) 6.59 (266) −57.2% (−65.5, −46.9) −42.1% (−54.1, −26.9)
NVT  4.73 (189) 6.22 (249) 5.92 (239) −45.6% (−58.3, −29.1) 3.4% (−23.7, 40.3)
VT  3.38 (135) 3.30 (132) 0.67 (27) −86.3% (−91.6, −78.4) −87.0% (−92.0, −79.5)
65+  yrs.
All 31.09 (258) 32.08 (268) 26.48 (230) −4.9% (−24.4, 19.5) 0.0% (−20.7, 26.1)
NVT  15.06 (125) 17.00 (142) 24.12 (210) +46.5% (9.0, 97.4) 64.7% (21.4, 124.0)
VT  16.03 (133) 15.08 (126) 2.30 (20) −80.4% (−88.6, −67.9) −80.5% (−88.6, −68.0)
Notes: The percentage change is a comparison of the predicted incidence in 2009/10 to the observed incidence in 2009/10 adjusting for the temporal trend pre-vaccination
(see  Methods). 95% conﬁdence intervals for the percentage changes are derived from the Poisson regression model. When serotype 1 is excluded, the percentage changes for
VT  differ slightly because inﬂation in this case is assumed to distribute over all types.
Fig. 1. Incidence rates of vaccine type (VT) and non-vaccine type (NVT) IPD in Scotland, by age group.
Note:  All serotypes are included in the left hand column of graphs while serotype 1 is excluded from the right hand column of graphs. The top row are for those aged 0–4
years,  the middle row for those aged 5–64 years and the bottom row for those aged 65+ years. The grey vertical bar denotes the introduction of PCV7. For those aged 65+
years,  the ﬁrst grey vertical bar denotes the introduction of PPV23. The data are plotted as crosses, the dashed lines show the predicted post vaccination incidence based on
pre  vaccination trends and the predicted values from the poisson regression model are the points joined by the lines.
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Table 3
The association between ST and serotype among IPD cases in Scotland in the period prior to the introduction of PCV7 in September 2006.
STs associated with PCV7 serotypes STs not
associated with
PCV7 serotypes
HF PCV7-ST [12 STs] LF PCV7-ST
[154STs]
Non PCV7-[151
STs]
PCV7/Serotypes 9 36 113 124 138 156 162 176 205 206 246 311 269 entries 0
PNE004 0 0 0 0 0 0 0 0 40 37 56 0
PNE06B 0 0 0 0 25 1 0 37 0 0 0 0
PNE09V 0 0 0 1 0 13 102 0 0 1 0 0
PNE014 208 0 0 84 0 4 1 0 0 0 0 1
PNE18C 0 0 36 0 0 0 0 1 0 0 0 0
PNE19F 1 0 0 0 0 0 35 0 0 0 0 0
PNE23F 0 32 0 0 0 0 0 l 0 0 0 62
PCV7-ST serotypes 25 Serotypes not in
PCV7 but associated
with the STs linked to
PCV7
25 entries over all 25 serotypes and all 12 sequence types 683 entries 353 entries
NonPCV7- ST serotypes 22 differentSerotypes
not associated with
any ST linked to PCV7
0 0 145 entries
Serotypes not in PCV7 but associated with the STs linked to PCV7:.
PNE001, PNE003, PNE005, PNE008, PNE020, PNE034, PNE038, PNE06A, PNE07A, PNE07C, PNE07F, PNE09A, PNE09N, PNE11A, PNE15A, PNE15B, PNE15C, PNE16F, PNE17F,
PNE18B, PNE18F, PNE19A, PNE22F, PNE33C, PNE33F.
Serotypes not associated with any ST linked to PCV7:.
PNE002, PNE013, PNE021, PNE024, PNE027, PNE029, PNE031, PNE037, PNE041, PNE042, PNE10A, PNE10F, PNE12A, PNE12B, PNE12F, PNE18A, PNE22A, PNE23A, PNE24F,
PNE28F, PNE35B, PNE35F.
STs in the HF PCV7-ST group had more than 10 reports of co-occurrence with PCV7 serotypes. There are 779 entries for these 12 STs. In the full matrix there are 1048 reports
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howed a decrease despite the previously reported increase pre-
CV7. Only increases in 7F (128.5%; 95% CI (30%, 308.8%)) and 22F
126.7%; 95% CI (15%, 356.6%)) were found to be signiﬁcant when
llowing for pre-vaccination trends. The decrease in serotype 1 IPD
as mainly driven by those aged <5 years and 5–65 years.
.6. Trends in serotype and ST distribution post-PCV7
Post-PCV7, serotypes (23B (12 times), 28 (6), 6C (5), 12 (1), 16A
1), 17A (1), and 35C (1); 27 of 2213 isolates typed) and STs (164
Ts; 222 of 2203 isolates sequenced) not previously reported in
cotland were noted. 10% of the isolates sequenced were new STs
hilst only 1% of the isolates typed gave rise to new serotypes.
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ig. 2. Trends in the serotype distribution from 1999/2000 to 2009/2010.
ote: In the period 1999–2002 when only serogroup was available, the serotypes of PCV7 se
n  the period 2003–2006. A sensitivity analysis showed that this had minimal impact on 
CV7–serotypes in the PCV7 vaccine.
CV7 serotypes–serotypes in the PCV7 vaccine.
CV7-ST serotypes–serotypes not in the PCV7 vaccine but which are associated with STs 
onPCV7-ST serotypes–the remaining serotypes present among IPD cases prior to the int
he  7 PCV7 serotypes.
ost PCV7 serotypes–serotypes which have emerged post PCV7 (post September 2006).Amongst the 14 serotypes each accounting for at least 1% of IPD
cases post-PCV7 (Table 1, Part B), there were signiﬁcant increasing
trends in serotype 19A and 22F IPD, at rates of 40% and 34% per
year, respectively, and decreasing trends for serotypes 1 and 20, at
rates of 29% and 36% per year, respectively.
Eleven STs accounted for more than 1% of all STs reported in
IPD post-PCV7. ST306 decreased signiﬁcantly at a rate of 37% per
year, comparable with the decrease in serotype 1. ST199 and ST433
both exhibited signiﬁcant increases post-PCV7 with 25% and 51%
increases per year, respectively. ST199 was  principally associated
with serotype 19A and, to a lesser extent, 15B whilst ST433 was
almost universally associated with serotype 22F. Serotype 20 was
principally associated with ST235.
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rogroups were imputed based upon the distribution of serotypes within serogroups
the distributions presented.
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Fig. 3. Trends in the ST distribution from 2002/2003 to 2009/2010.
Note:  HF PCV7-ST–The 12 STs with a strong association with the PCV7 serotypes in the PCV7 vaccine. LF PCV7-ST–the remaining STs associated with the PCV7 vaccine
serotypes. NonPCV7-ST - STs not associated with any serotype in the PCV7 vaccine.
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.7. Association between serotypes and STs pre- and post-PCV7
Associations between serotypes and STs in the period prior to
CV7 use are shown in Table 3. PCV7 serotypes were associated
ith 166 STs, however only 12 STs (9, 36, 113, 124, 138, 156, 162,
76, 205, 206, 246, 311) account for the vast majority (74.3%) of the
PD cases. PCV7 serotypes, associated with these 12 STs (labelled
CV7-HF PCV7-ST), were responsible for 779 IPD cases. Another 269
ases were caused by PCV7 serotypes associated with the remaining
54 STs (labelled PCV7-LF PCV7-ST).
Regarding NVT serotypes associated with the 166 STs linked to
CV7, 25 different serotypes were responsible for 708 IPD cases,
f which only 25 were linked with HF PCV7-STs. The other 683
ere associated with the remaining 154 low frequency STs (cross-
lassiﬁcation of PCV7-ST serotypes and LF PCV7-ST). The 25 PCV7-
T serotypes had associations (353 cases) with 151 STs not directly
ssociated with PCV7 (cross-classiﬁcation of PCV7 ST serotypes and
onPCV7-ST). Finally these 151 NonPCV7-STs were associated with
2 NonPCV7-ST serotypes (145 cases) with no direct link with any
T linked to PCV7.
Trends in the distribution of groups of serotypes and STs are pre-
ented in Fig. 2 and Fig. 3, respectively. Both show a relatively stable
istribution in the pre-PCV7 period. The serotype distribution has
hanged in favour of those serotypes which were associated with
Ts shown to have had an association with serotypes in PCV7–the
CV7-ST serotypes. Before 2006/07, these serotypes formed ∼40%
f all serotypes but formed 80% in 2009/10. The NonPCV7-ST
erotypes formed 6% of serotypes prior to 2006/07, rising to 8%
n 2008/09 and 11% in 2009/10. The ratio of the percentage of
onPCV7-ST serotypes to the percentage of PCV7-ST serotypes has
emained relatively constant over the whole period. The ST dis-
ribution did not change as dramatically but the 12 HF PCV7-STs
ecreased while the remaining LF PCV7-STs and STs not associ-
ted with PCV7 increased by about 10% each. New post-PCV7 STs
ccounted for ∼10% of STs in 2009/10. There was  some evidence of
impson’s Paradox, with the aggregation masking differing trends
n the serotype–ST association. Further examination showed that
he rise in LF PCV7-STs was associated with PCV7-ST serotypes
hile the rise in the NonPCV7-STs is more associated with PCV7-ST
erotypes than NonPCV7-ST serotypes.4. Summary
Amongst non-PCV7 serotypes and STs not primarily associated
with these serotypes, there was some evidence of a change in
the distribution. IPD from NVT serotypes 19A and 22F increased,
whilst serotype 20 showed a decrease. Serotypes 19A and 22F were
linked to LF PCV7-STs, the group of serotypes which showed an
increase. Serotype 20 was not linked to PCV7-STs and, on the whole,
this group of serotypes was  relatively static compared to PCV7-ST
serotypes.
5. Discussion
Prior to routine PCV7 use, the distribution of serotypes and STs
in Scottish IPD appeared static, only serotype 1 IPD was  found to
increase, alongside an increase in ST306 IPD. Routine PCV7 vaccina-
tion drastically reduced the burden of VT IPD in Scotland, not only
among children targeted for vaccination but also the rest of the pop-
ulation. Little evidence of serotype replacement was found except
for the elderly where increases in NVT IPD outbalanced decreases in
VT IPD. The major replacement serotypes were 19A and 22F along-
side STs 199 and 433. Routine collection of information on both
the genetic background and capsular serotype allowed an analysis
of relationships in response to vaccine implementation. Interest-
ingly, the proportional increase of serotypes after vaccination was
greatly attributable to serotypes which were associated with PCV7
STs. This implies that ST perhaps plays a role in determining the
ﬁtness of a pneumococcus and that it may  be possible to predict
serotypes likely to increase most following the use of increased
valency vaccines by examining STs associated with VT serotypes
and identifying the NVT serotypes also found to be associated with
these STs. It is important to note, however, that STs linked to dis-
ease causing serotypes in the developing world may not correspond
with those in the developed world (e.g., outbreaks attributable to
serotype 1 in sub-Saharan Africa were associated with ST 618 and
217, not 306 and 227 as in the developed world) [28]. Therefore,
results presented here may  not be applicable worldwide.
Our ﬁndings on pre and post-vaccination trends correspond to
existing literature. Serotype 1 bacteraemia was found to increase
over time in the UK and Ireland [29], as well as serotype 1 IPD
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n England and Wales [25]. Furthermore, the increase observed in
erotype 19A IPD has been widely observed [13–16,30–32].
Following PCV7 use, VT serotypes were almost eliminated from
PD in those aged <5 years, providing clear evidence of a strong vac-
ine effect in this group, as has been documented in other countries
33–35]. Furthermore, there appears to be evidence of herd protec-
ion in those aged 5–64 years, as well as those aged ≥65 years,
orresponding with herd protection observed elsewhere, with sus-
ained beneﬁts of PCV7 use in preventing VT serotypes recently
ocumented [36]. Among those aged ≥65 years, there is evidence
f serotype replacement with an increase in NVT incidence, also
hown in the USA and elsewhere [37,38]. This serotype replace-
ent may  be attributable to PPV23 use; however, the timing of
he observed decline does not correspond with this introduction.
mong those aged <5 and 5–64 years, serotype replacement is less
lear, masked by serotype 1 IPD which was increasing prior to
CV7 use before decreasing. However, adjusting for this, serotype
eplacement in these groups has been less pronounced in Scotland
han reported in England and Wales [25] and elsewhere [39,40]. It is
nclear why Scotland is different to England and Wales. One possi-
ility could be replacement in the nasopharynx of Scottish residents
y opportunistic NVTs which predominantly cause IPD in those
65 years. Studying changes in nasopharyngeal carriage before and
fter PCV7 use, as done elsewhere [41,42], could shed more light
n this. These studies found no reduction in overall carriage due to
ncreased NVT carriage following PCV7 introduction. Huang et al.
dentiﬁed evidence of increased carriage of NVT serotype 29 and
n increase in serotype 15; Flasche et al. report increases in car-
iage of several NVT serotypes (33F, 7F, 10A, 34, 15B, 31, 21, 3, 19A,
5C, and 23A) following PCV7 use. In the UK, serotypes 3 and 19A
ere the most prevalent IPD causing serotypes in those aged >65
ears from 2008–2010 [43], potentially due to increased carriage
f these serotypes post-PCV7 introduction. Therefore, it would be
f interest to examine changes in serotype carriage post-PCV7 in
cotland.
A strength of this study is that Scottish IPD data can be con-
idered as a complete national data set as >90% of pneumococci
solated from IPD patients in Scotland are sent to the SHLMPRL [44].
lthough there has not been an investigation of changes in sensitiv-
ty of IPD reporting due to PCV7 use in Scotland, no changes were
nticipated as the surveillance system has not altered. By using
ogistic and poisson regression to model linear trends, evidence of
hanges in the serotype and ST epidemiology can be identiﬁed.
The 13-valent PCV (PCV13) contains the PCV7 serotypes, as well
s 1, 3, 5, 6A, 7F and 19A. PCV13 was introduced in the UK in
010 and should aid in the prevention of further IPD, however as
here will be serotypes linked to those in PCV13 through STs asso-
iated with PCV13 serotypes, a change in serotype distribution can
erhaps be anticipated due to increases in those linked serotypes.
herefore, it is important to continue to monitor STs, as well as
erotypes, associated with cases of IPD to aid in determining the
ong-term effectiveness of serotype-speciﬁc vaccine interventions
nd to guide development of future vaccines.
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